Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
18
CSTL Quote, Financials, Valuation and Earnings
Last price:
$24.86
Seasonality move
:
-10.09%
Day range:
$24.09 - $25.22
52-week range:
$14.59 - $44.28
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
2.09x
P/B ratio:
1.56x
Volume:
288.5K
Avg. volume:
404.9K
1-year change:
23.03%
Market cap:
$732.9M
Revenue:
$344.2M
EPS (TTM):
-$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$79.3M | -$0.49 | -9.89% | -45.91% | $48.50 |
|
ASRT
Assertio Holdings, Inc.
|
$11.3M | -$0.91 | -57.25% | -543.11% | $38.25 |
|
CTSO
CytoSorbents Corp.
|
$9.4M | -$0.07 | 7.71% | -41.38% | $5.25 |
|
DCTH
Delcath Systems, Inc.
|
$23.6M | -$0.09 | 19.07% | -44.65% | $21.33 |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$228.4M | $0.93 | 23.65% | 19.24% | $42.00 |
|
ODYY
Odyssey Health, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$24.84 | $48.50 | $732.9M | 30.24x | $0.00 | 0% | 2.09x |
|
ASRT
Assertio Holdings, Inc.
|
$19.21 | $38.25 | $119.1M | -- | $0.00 | 0% | 4.52x |
|
CTSO
CytoSorbents Corp.
|
$0.58 | $5.25 | $38.4M | -- | $0.00 | 0% | 1.00x |
|
DCTH
Delcath Systems, Inc.
|
$9.63 | $21.33 | $337.4M | 154.63x | $0.00 | 0% | 4.45x |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$27.74 | $42.00 | $1.6B | 10.16x | $0.00 | 0% | 1.86x |
|
ODYY
Odyssey Health, Inc.
|
$0.0628 | -- | $6.3M | 0.41x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
7.29% | 1.198 | 3.21% | 4.99x |
|
ASRT
Assertio Holdings, Inc.
|
29.99% | -3.627 | 69.16% | 1.46x |
|
CTSO
CytoSorbents Corp.
|
83.14% | 2.188 | 72.52% | 1.49x |
|
DCTH
Delcath Systems, Inc.
|
0.84% | 0.850 | 0.27% | 9.39x |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
21.27% | 0.603 | 10.88% | 3.46x |
|
ODYY
Odyssey Health, Inc.
|
-27.26% | 5.553 | 31.48% | 0.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$66M | -$3.8M | -4.92% | -5.28% | -4.4% | $19.7M |
|
ASRT
Assertio Holdings, Inc.
|
$4.4M | -$9.1M | -20.53% | -29.06% | -67.56% | -$30M |
|
CTSO
CytoSorbents Corp.
|
$6.8M | -$4.1M | -21.56% | -78.59% | -43.87% | -$2.5M |
|
DCTH
Delcath Systems, Inc.
|
$17.7M | -$2.2M | 2.78% | 2.81% | -10.54% | $7.7M |
|
HRMY
Harmony Biosciences Holdings, Inc.
|
$169.3M | $38.6M | 15.97% | 20.57% | 15.82% | $106.8M |
|
ODYY
Odyssey Health, Inc.
|
-- | -$181.9K | -- | -- | -- | -$284.3K |
Castle Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CSTL or ASRT?
Assertio Holdings, Inc. has a net margin of -2.68% compared to Castle Biosciences, Inc.'s net margin of -88.08%. Castle Biosciences, Inc.'s return on equity of -5.28% beat Assertio Holdings, Inc.'s return on equity of -29.06%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.75.87% -$0.08 $507.9M ASRTAssertio Holdings, Inc.32.77% -$1.86 $134.2M -
What do Analysts Say About CSTL or ASRT?
Castle Biosciences, Inc. has a consensus price target of $48.50, signalling upside risk potential of 95.25%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $38.25 which suggests that it could grow by 99.12%. Given that Assertio Holdings, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ASRTAssertio Holdings, Inc.3 0 0 -
Is CSTL or ASRT More Risky?
Castle Biosciences, Inc. has a beta of 1.184, which suggesting that the stock is 18.391% more volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.642%.
-
Which is a Better Dividend Stock CSTL or ASRT?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or ASRT?
Castle Biosciences, Inc. quarterly revenues are $87M, which are larger than Assertio Holdings, Inc. quarterly revenues of $13.5M. Castle Biosciences, Inc.'s net income of -$2.3M is higher than Assertio Holdings, Inc.'s net income of -$11.9M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.09x versus 4.52x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.09x 30.24x $87M -$2.3M ASRTAssertio Holdings, Inc.4.52x -- $13.5M -$11.9M
-
Which has Higher Returns CSTL or CTSO?
CytoSorbents Corp. has a net margin of -2.68% compared to Castle Biosciences, Inc.'s net margin of -59.53%. Castle Biosciences, Inc.'s return on equity of -5.28% beat CytoSorbents Corp.'s return on equity of -78.59%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.75.87% -$0.08 $507.9M CTSOCytoSorbents Corp.73.68% -$0.09 $35M -
What do Analysts Say About CSTL or CTSO?
Castle Biosciences, Inc. has a consensus price target of $48.50, signalling upside risk potential of 95.25%. On the other hand CytoSorbents Corp. has an analysts' consensus of $5.25 which suggests that it could grow by 800.52%. Given that CytoSorbents Corp. has higher upside potential than Castle Biosciences, Inc., analysts believe CytoSorbents Corp. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CTSOCytoSorbents Corp.1 1 0 -
Is CSTL or CTSO More Risky?
Castle Biosciences, Inc. has a beta of 1.184, which suggesting that the stock is 18.391% more volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.189%.
-
Which is a Better Dividend Stock CSTL or CTSO?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CTSO?
Castle Biosciences, Inc. quarterly revenues are $87M, which are larger than CytoSorbents Corp. quarterly revenues of $9.2M. Castle Biosciences, Inc.'s net income of -$2.3M is higher than CytoSorbents Corp.'s net income of -$5.5M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.09x versus 1.00x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.09x 30.24x $87M -$2.3M CTSOCytoSorbents Corp.1.00x -- $9.2M -$5.5M
-
Which has Higher Returns CSTL or DCTH?
Delcath Systems, Inc. has a net margin of -2.68% compared to Castle Biosciences, Inc.'s net margin of -9.15%. Castle Biosciences, Inc.'s return on equity of -5.28% beat Delcath Systems, Inc.'s return on equity of 2.81%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.75.87% -$0.08 $507.9M DCTHDelcath Systems, Inc.85.48% -$0.05 $112.2M -
What do Analysts Say About CSTL or DCTH?
Castle Biosciences, Inc. has a consensus price target of $48.50, signalling upside risk potential of 95.25%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 121.53%. Given that Delcath Systems, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Delcath Systems, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 DCTHDelcath Systems, Inc.5 0 0 -
Is CSTL or DCTH More Risky?
Castle Biosciences, Inc. has a beta of 1.184, which suggesting that the stock is 18.391% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.086%.
-
Which is a Better Dividend Stock CSTL or DCTH?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or DCTH?
Castle Biosciences, Inc. quarterly revenues are $87M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.7M. Castle Biosciences, Inc.'s net income of -$2.3M is lower than Delcath Systems, Inc.'s net income of -$1.9M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Delcath Systems, Inc.'s PE ratio is 154.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.09x versus 4.45x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.09x 30.24x $87M -$2.3M DCTHDelcath Systems, Inc.4.45x 154.63x $20.7M -$1.9M
-
Which has Higher Returns CSTL or HRMY?
Harmony Biosciences Holdings, Inc. has a net margin of -2.68% compared to Castle Biosciences, Inc.'s net margin of 9.22%. Castle Biosciences, Inc.'s return on equity of -5.28% beat Harmony Biosciences Holdings, Inc.'s return on equity of 20.57%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.75.87% -$0.08 $507.9M HRMYHarmony Biosciences Holdings, Inc.69.44% $0.38 $1.1B -
What do Analysts Say About CSTL or HRMY?
Castle Biosciences, Inc. has a consensus price target of $48.50, signalling upside risk potential of 95.25%. On the other hand Harmony Biosciences Holdings, Inc. has an analysts' consensus of $42.00 which suggests that it could grow by 51.41%. Given that Castle Biosciences, Inc. has higher upside potential than Harmony Biosciences Holdings, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Harmony Biosciences Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 HRMYHarmony Biosciences Holdings, Inc.4 4 0 -
Is CSTL or HRMY More Risky?
Castle Biosciences, Inc. has a beta of 1.184, which suggesting that the stock is 18.391% more volatile than S&P 500. In comparison Harmony Biosciences Holdings, Inc. has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.676%.
-
Which is a Better Dividend Stock CSTL or HRMY?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harmony Biosciences Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Harmony Biosciences Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or HRMY?
Castle Biosciences, Inc. quarterly revenues are $87M, which are smaller than Harmony Biosciences Holdings, Inc. quarterly revenues of $243.8M. Castle Biosciences, Inc.'s net income of -$2.3M is lower than Harmony Biosciences Holdings, Inc.'s net income of $22.5M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Harmony Biosciences Holdings, Inc.'s PE ratio is 10.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.09x versus 1.86x for Harmony Biosciences Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.09x 30.24x $87M -$2.3M HRMYHarmony Biosciences Holdings, Inc.1.86x 10.16x $243.8M $22.5M
-
Which has Higher Returns CSTL or ODYY?
Odyssey Health, Inc. has a net margin of -2.68% compared to Castle Biosciences, Inc.'s net margin of --. Castle Biosciences, Inc.'s return on equity of -5.28% beat Odyssey Health, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.75.87% -$0.08 $507.9M ODYYOdyssey Health, Inc.-- -$0.03 -$8.3M -
What do Analysts Say About CSTL or ODYY?
Castle Biosciences, Inc. has a consensus price target of $48.50, signalling upside risk potential of 95.25%. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Castle Biosciences, Inc. has higher upside potential than Odyssey Health, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Odyssey Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ODYYOdyssey Health, Inc.0 0 0 -
Is CSTL or ODYY More Risky?
Castle Biosciences, Inc. has a beta of 1.184, which suggesting that the stock is 18.391% more volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.363, suggesting its less volatile than the S&P 500 by 236.315%.
-
Which is a Better Dividend Stock CSTL or ODYY?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or ODYY?
Castle Biosciences, Inc. quarterly revenues are $87M, which are larger than Odyssey Health, Inc. quarterly revenues of --. Castle Biosciences, Inc.'s net income of -$2.3M is higher than Odyssey Health, Inc.'s net income of -$3.6M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.09x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.09x 30.24x $87M -$2.3M ODYYOdyssey Health, Inc.-- 0.41x -- -$3.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
